Opko Health Inc.
OPKOpko Health Inc. is a healthcare company specializing in the development of innovative diagnostics and pharmaceuticals. Founded in 2007, the company focuses on personalized medicine, providing diagnostic tests and treatments in areas such as oncology, neurology, and infectious diseases. Its portfolio includes bio-pharmaceutical products, laboratory services, and consumer health products aimed at improving patient outcomes through targeted healthcare solutions.
Company News
Entera Bio's CEO will participate in the Evercore ISI Healthcare Conference, highlighting the company's progress in developing oral peptide therapies for conditions like osteoporosis and hypoparathyroidism.
NextPlat Corp provides an update on its strategic progress across healthcare services, communications, and e-commerce channels, highlighting cost reduction efforts, new contracts, and technology investments aimed at driving growth and profitability.
Entera Bio reported better-than-expected Q2 2025 earnings with a GAAP EPS of $0.06, secured FDA regulatory concurrence for EB613's Phase 3 trial, and maintained a strong cash position of $18.8 million to support operations through mid-Q3 2026.
NextPlat's interim CEO David Phipps outlined strategic plans to improve healthcare and e-commerce divisions, focusing on operational efficiency, cost reduction, and exploring growth opportunities following the unexpected passing of former CEO Charles M. Fernandez.
OPKO Health, Inc. and Entera Bio Ltd. announced that OPKO's ModeX Therapeutics division has formed a Scientific Advisory Board with leaders in immunology and oncology drug development. Additionally, OPKO and Entera's first-in-class dual GLP-1/Glucagon tablet candidate for obesity and metabolic disorders has been selected for presentation at the E...
